
The petosemtamab and pembrolizumab combination met both primary endpoints in a Phase 3 trial of PD-L1-positive head and neck cancer.
Genmab said its petosemtamab and pembrolizumab combination reduced the risk of death by 50% versus pembrolizumab alone in a Phase 3 trial. The first interim analysis found the treatment met both primary endpoints in patients with PD-L1-positive recurrent or metastatic head and neck cancer.
The trial also found a statistically significant improvement in objective response rate, regardless of patients’ HPV status. Genmab said the combination’s safety profile was generally well tolerated, with no new safety signals identified.
As of Wednesday at 4 p.m. EDT, Genmab shares traded at $57.29, up 28.25% since the previous close. The company plans to engage global regulatory authorities and submit full trial results for presentation at a future medical meeting.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.